Mallinckrodt and Endo , drugmakers which recently emerged from bankruptcy after a wave of U.S. opioid lawsuits, announced ...

Ireland’s Mallinckrodt will buy U.S. drugmaker Endo in a cash-and-stock deal valued at $6.7 billion. The companies said ...

The new entity will be listed on the New York Stock Exchange and is expected to generate pro forma revenue of $3.6 billion in ...

Mallinckrodt and Endo are exploring a potential merger that could be valued at about $7 billion, person familiar with the ...

Mallinckrodt Pharmaceuticals and Endo Inc. are exploring a potential merger that could be valued at about $7 billion, people ...

(Reuters) - Mallinckrodt and Endo, drugmakers with a shared history of facing U.S. opioid litigation, have agreed to merge in ...

The two companies are merging after previously filing for bankruptcy due to opioid-related litigation and financial losses.

Drugmaker Mallinckrodt struck a deal to buy Endo in an effort to build a diversified pharmaceuticals company with a hefty U.S ...

Dublin-headquartered Mallinckrodt is taking over smaller rival Endo and planning to list the combined firm on the New York ...

Endo (NDOI) stock gains as the company is in pact with Mallinckrodt (MNKTQ) to merge in a $6.7B deal, creating a Dublin-based ...

Mallinckrodt and Endo are merging in a cash and stock deal worth some $6.7 billion, the companies said Thursday. Under the ...

Mallinckrodt and Endo are merging in a $6.7 billion deal, with a pro forma NYSE listing and $900 million in financing.